Floatz logo

Theprubicin

Neoplasm Metastases

National Institutes of Health Clinical Center (CC)Small moleculePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Neoplasm Metastases cohort.

Asset / SponsorPhaseRating
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Trabectedin
Janssen Research & Development, LLC
Phase 1/2B
Ketoconazole
Janssen Research & Development, LLC
Phase 1/2CCC
Alpha-Gal Glycosphingolipid
University of Massachusetts, Worcester
Phase 1CC
G 207
M.D. Anderson Cancer Center
Phase 1CC

Same molecule, other indications

Theprubicin is also rated in:

hepatocellular carcinomaDormant
BB
Indicative ·
71 / 100
View asset →
Transarterial ChemoembolizationDormant
BB
Indicative ·
66 / 100
View asset →
Colon Cancer Liver MetastasisDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →